Patients ask us about peptides for recovery more than almost any other topic in our wellness practice, usually after reading about them online or hearing about them from a training partner. The interest is real, but so is the confusion. Peptides for recovery cover a wide range of compounds, and for recovery and sleep, the human research behind most of them is limited or very early. This article walks through what these therapies are, what patients pursue them for, what the evidence currently does and does not support, and what they cost at our Gainesville clinic. None of this replaces a physician evaluation, and none of it is a substitute for a conversation with Dr. Carolyn Indianos about your specific health history.
What to Know
- Peptides are short chains of amino acids. Some are FDA-approved medications, others are compounded preparations used off-label, and some are still primarily research compounds.
- Patients typically pursue them for recovery from training or injury, sleep quality, and general wellness support, not as a treatment or cure for a diagnosed disease.
- BPC-157 and several other research peptides have been reviewed by the FDA under its 503A bulk drug substances program, which identified safety concerns and limits how they can be legally compounded.
- Human clinical evidence for peptides like BPC-157 is limited and largely comes from animal studies. Evidence that growth-hormone-releasing peptides like CJC-1295 and Ipamorelin improve adult recovery or sleep is also limited.
- These are prescription and compounded therapies. They require a physician evaluation, lab work, and ongoing medical oversight, not self-directed use.
- Pricing varies by peptide and protocol. CJC-1295/Ipamorelin is priced at $450 per month. BPC-157 and TB-500 pricing is discussed at consultation, per physician policy.
What Peptides Are, and Why Patients Ask About Them
A peptide is simply a short chain of amino acids, smaller than a full protein. The body already produces and uses thousands of peptides for everyday signaling, from hormone release to tissue repair. In a clinical setting, “peptide therapy” usually refers to a small group of synthetic or compounded peptides that are prescribed to support specific goals: tissue recovery, sleep quality, or the body’s natural growth-hormone signaling pathway.
It is worth separating three categories up front, because they are regulated and studied very differently:
- FDA-approved peptide medications used off-label for wellness purposes. Note that sermorelin’s original branded product (Geref) was approved only for growth hormone deficiency in children and was discontinued in the United States in 2008, so any sermorelin prepared today is compounded and not FDA-approved.
- Compounded peptides, such as CJC-1295/Ipamorelin blends, BPC-157, and TB-500. These are not FDA-approved products.
- Research-stage compounds with limited human trial data, where most available evidence comes from cell and animal studies.
At our peptide therapy program, every patient starts with a consultation and lab review with Dr. Indianos before any peptide is prescribed. Individual results vary, and no peptide is presented to patients as a guaranteed outcome.
Peptides for Recovery
When patients ask about peptides for recovery, they are usually referring to compounds studied for a possible role in the body’s tissue repair processes after training, minor injury, or general physical strain. The two most commonly discussed in this category are BPC-157 and TB-500.
BPC-157 is a peptide derived from a protein found in gastric juice. It has been studied in animal models for its role in tissue and gut healing, and it has become popular in wellness and performance circles as a result. Human clinical trial data remains limited. The FDA has reviewed BPC-157 under its 503A bulk drug substances program and identified safety risk concerns, which means pharmacies face real restrictions on how (and whether) they can prepare it. We do not present BPC-157 as a treatment for any diagnosed injury or disease. Patients who ask about it are told plainly where the evidence stands and where it does not. Learn more on our BPC-157 therapy page.
TB-500 is a synthetic version of a fragment of the naturally occurring protein thymosin beta-4, also researched primarily in animal and laboratory settings for its role in cell migration and tissue repair. As with BPC-157, human evidence is preliminary. Neither BPC-157 nor TB-500 has ever been FDA-approved for any use.
Peptides for Sleep and the Growth-Hormone Axis
The second major reason patients search for peptides for sleep is the growth-hormone-releasing family: sermorelin, CJC-1295, and Ipamorelin. These peptides work upstream, prompting the pituitary gland to release growth hormone in a manner closer to the body’s natural pulsatile pattern, rather than introducing growth hormone directly.
Sermorelin is a growth-hormone-releasing hormone (GHRH) analog. Its branded version (Geref) was FDA-approved only for growth hormone deficiency in children and was discontinued in 2008, and that history does not establish benefits for adult recovery or sleep. Compounded sermorelin is not FDA-approved. Some patients report changes in sleep quality or recovery, but evidence in adults is limited, individual results vary, and it is not a treatment for a sleep disorder. Details are on our sermorelin therapy page.
CJC-1295 and Ipamorelin are often discussed together: CJC-1295 is designed to extend the duration of growth-hormone release, and Ipamorelin to stimulate that release more selectively. Neither is FDA-approved, and long-term human safety and benefit data are limited. Patients pursue this combination for recovery from exercise, sleep quality, and body composition support as part of a broader wellness plan, not as a stand-alone cure for any condition. More detail is on our CJC-1295 and Ipamorelin page.
None of these peptides are approved by the FDA for sleep improvement as a labeled indication. Growth hormone release is linked with deep sleep, but evidence that these peptides improve sleep in healthy adults is limited, and patient reports vary.
What the Evidence Actually Supports
It helps to be specific rather than general here. The peptides discussed in this article fall into different evidence tiers:
- Longer history, limited adult evidence: Sermorelin has a longer research history, mostly from its past approved use in children with growth hormone deficiency. That history does not establish benefits for adult recovery or sleep, and compounded sermorelin is not FDA-approved.
- Limited evidence: CJC-1295 and Ipamorelin have pharmacology data showing effects on growth hormone release, but human trials showing benefits for wellness, recovery, or sleep are lacking.
- Preliminary evidence: BPC-157 and TB-500 are supported mostly by animal and in-vitro research. Human clinical trials are sparse, and the regulatory status reflects that gap. Patients should understand that popularity and evidence are not the same thing.
We do not claim that any peptide treats, cures, or heals a diagnosed medical condition. Peptide therapy at our clinic is positioned as physician-supervised wellness support, discussed honestly in terms of what current research does and does not establish.
Safety and Regulatory Status
This is the part of the conversation we take most seriously. In recent years, the FDA reviewed a group of substances, including BPC-157, for potential inclusion on the 503A bulk drug substances list, which governs what compounding pharmacies may legally prepare. The FDA’s review identified safety risk concerns for BPC-157. Its exact standing in that program has shifted over time, and the agency’s published lists are the authority on its status on any given day. That placement is a meaningful regulatory signal, and we do not soften it for patients. The FDA’s own list of bulk drug substances that may present significant safety risks names BPC-157 directly, citing potential immunogenicity for certain routes of administration, complexities around peptide-related impurities, and limited available safety information.
In practical terms, this means:
- None of the compounded peptides discussed here are FDA-approved drugs, which means the FDA has not reviewed them for safety, effectiveness, or quality.
- Compounding access and legal status for peptides like BPC-157 can shift as FDA guidance evolves, which is one reason a physician relationship matters more than a one-time purchase.
- Peptides sourced outside a licensed pharmacy and a physician relationship, such as through research-chemical vendors, carry additional and different risks: unverified purity, incorrect labeling, and no clinical oversight.
- Every patient we treat with peptide therapy is evaluated by Dr. Indianos, including relevant history and lab work, before a prescription is written, and is followed up with ongoing medical supervision.
What Peptide Therapy Costs
Pricing depends on which peptide protocol fits your goals and is confirmed during your consultation with Dr. Indianos. As a general reference, current published pricing at our clinic is:
- CJC-1295/Ipamorelin: $450 per month.
- BPC-157 and TB-500: pricing is discussed at consultation, per Dr. Indianos’s policy, given the individualized nature of these protocols and their regulatory status.
Pricing above is current as of publication and is confirmed at your consultation, since protocols and compounding availability can change.
Comparing Peptide Categories
| Peptide Category | What Patients Pursue It For | How It Is Generally Administered | Evidence Status | Regulatory Status |
|---|---|---|---|---|
| BPC-157 | Recovery support after training or minor strain | Compounded injectable, prescribed and supervised | Preliminary, mostly animal and lab studies | Compounded, not FDA-approved; FDA 503A review: safety risk concerns identified |
| TB-500 | Recovery support after training or minor strain | Compounded injectable, prescribed and supervised | Preliminary, mostly animal and lab studies | Compounded, not FDA-approved |
| Sermorelin | General wellness support, sleep quality, recovery | Compounded injectable, prescribed and supervised | Past approved use in children only; limited adult evidence | Compounded, not FDA-approved |
| CJC-1295/Ipamorelin | Recovery, sleep quality, body composition support | Compounded injectable, prescribed and supervised | Limited; pharmacology data, few human trials | Compounded, not FDA-approved |
Frequently Asked Questions
Is peptide therapy safe?
Peptide therapy carries different safety considerations depending on the specific peptide, and it is only appropriate when prescribed and supervised by a physician after a health history and lab review. Some peptides, including BPC-157, were flagged by the FDA for significant safety risk concerns as part of the agency’s 503A bulk drug substances review, and human clinical data for that class remains limited. Sermorelin has a longer history, but its past FDA approval was only for children with growth hormone deficiency, and compounded sermorelin is not FDA-approved. Sourcing matters too: peptides obtained outside a licensed pharmacy and physician relationship carry additional risks around purity and accurate labeling that a clinical protocol is designed to avoid. This is why we do not offer peptides without an evaluation with Dr. Indianos.
What is the difference between peptides for recovery and peptides for sleep?
The distinction is more about intent than mechanism. BPC-157 and TB-500 are typically discussed in the context of tissue and training recovery. Sermorelin, CJC-1295, and Ipamorelin work through the growth-hormone pathway, and some patients report sleep-related changes, though evidence in adults is limited and these peptides are not sedatives. Human evidence for either purpose is limited, which is part of the conversation at consultation.
How much does peptide therapy cost?
CJC-1295/Ipamorelin is currently priced at $450 per month at our clinic. BPC-157 and TB-500 pricing is discussed individually at consultation. Pricing is confirmed at the time of your visit, since it can change and depends on your specific protocol.
Are peptides like BPC-157 FDA-approved?
No. BPC-157 has never been FDA-approved for any use, and the FDA has identified safety risk concerns for it under the 503A bulk drug substances program. Patients should understand this distinction clearly before starting any protocol.
Do I need a prescription for peptide therapy?
Yes. Every peptide discussed in this article is a prescription or compounded medical product. It requires an evaluation by a licensed physician, appropriate lab work, and ongoing medical supervision. Peptides are not offered on a self-directed or over-the-counter basis at our clinic.
Medically reviewed by Dr. Carolyn Indianos, MD, Founder and Medical Director, Bespoke Aesthetics. Last updated September 2026.
If a clinic is willing to sell you a peptide without labs, a history, and a frank conversation about what the evidence does not yet show, that tells you something. The next step here is a consultation with Dr. Indianos, where your health history, goals, and lab work decide whether any of this is appropriate for you, and where the honest answer is sometimes no. Call our Gainesville clinic at 352-450-1004 or contact us to schedule.
